Dr Alan G. Ramsay
Senior Lecturer in Lymphoma Biology
Tel: +44 (0)20 7848 5816
Dr Ramsay's Profile
Dr. Ramsay leads a research group focussing on translational research in
cancer immunology. His research in the chronic lymphocytic leukaemia
(CLL) and lymphoma field has characterised novel tumour cell-induced
T-cell immune evasion mechanisms and translated bench science to
clinical trials with immunotherapy (Ramsay et al JCI 2008) (Shanafelt and
Ramsay et al Blood 2013) (Ramsay Br. J Haematol. 2013).
includes pre-clinical defintion of CLL (Ramsay et al Blood 2012) and
lymphoma (Ramsay et al Blood 2009) tumour cells co-opting multiple
immune checkpoint (IC) molecules to suppress T-cell lytic immune synapse
function ('adaptive immune resistance').
Current research focus
Understanding and overcoming ‘microenvionmental immunosuppression’ in order to identify new targets for repairing anti-tumour immunity.
2014 – 2016 British Society for Haematology (BSH) Investigator Start-up Fellowship.
2010 – 2012 European Hematology Association (EHA) Research Fellowship.
- PhD PostGraduate Coordinator (PGC) for Haemato-Oncology, Division of Cancer.
- Undergraduate and MSc/Res teaching and project supervision.
- Kater AP, Tonino SH, Egle A, Ramsay AG. How does lenalidomide target the chronic lymphocytic leukemia microenvionment? Blood. 2014
- Kiaii S, Clear AJ, Ramsay AG, Davis D, Sangaralingam A, Lee A, Calminici M, Neuberg D, Gribben JG. Follicular lymphoma cells induce changes on T-cell gene expression and function – potential impact on survival and risk of transformation. J Clin Oncol. 2013; 31(21):2254-61.
- Shanafelt TD, Ramsay AG (co-first author), Zent CS, Leis J, Tun HW, Call TG, LaPlant B, Bowen D, Pettinger A, Jelinek DF, Hanson CA, Kay NE. Long-term repair of T-cell synapse activity in a phase 2 trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia. Blood. 2013;121(20):4137-4141.
- Ramsay AG, Evans R, Kiaii S, Svensson L, Hogg N, Gribben JG. Chronic lymphocytic leukemia cells induce defective LFA-1-directed T cell motility by altering Rho GTPase signaling that is reversible with lenalidomide. Blood. 2013; 121(14):2704-2714.
(InsideBlood research highlight)
- Ramsay AG, Clear AJ, Fatah R, Gribben JG. Multiple inhibitory ligands induce impaired T cell immunological synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer.
- Ramsay AG. Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity. Br J Haematol. 2013;162(3):313-325.
- Ramsay AG, Clear AJ, Kelly G, et al. Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. Blood. 2009;114(21):4713-4720.
- Gorgun G, Ramsay AG (co-first author), Holderried TA, et al. E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction. Proc Natl Acad Sci USA. 2009;106(15):6250-6255.
- Ramsay AG, Johnson AJ, Lee AM, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest. 2008;Jul;118(7):2427-2437.
- Ramsay AG, Keppler MD, Jazayeri M, et al. HS1-associated protein X-1 regulates carcinoma cell migration and invasion via clathrin-mediated endocytosis of integrin alphavbeta6. Cancer Res. 2007;67(11):5275-5284.